ABEO · Abeona Therapeutics Inc.
$5.99
-0.36 (-5.67%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited interim condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$342.25M
Shares
57.18M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Edward Carr | Former Chief Accounting Officer and Chief Financial Officer | $1,569,879 |
| Brendan O’Malley | General Counsel | $1,179,209 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | Former President and Chief Executive Officer Fair value of option awards is calculated under ASC 718 as of the grant date using the Black-Scholes option-pricing model and as of the repricing date using a Hull-White I lattice model. Employees are assumed to exercise their options. The determination of the fair value of share-based payment awards made on the date of grant is affected by our Common Stock price as well as assumptions regarding a number of complex and subjective variables. Our assumptions in determining fair value are described in Note 11 of Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report. | $1,499,160 |
| Edward Carr | Former Chief Accounting Officer and Chief Financial Officer | $924,007 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Amoroso | member of the Board of Directors | Resigned | 2026-06-12 |
| Keith A. Goldan | member of the Board of the Company as a Class 1 director | Appointed | 2026-04-07 |
| Eric Crombez | member of the Board | Appointed | 2024-08-14 |
| Bernhardt G. Zeiher | member of the Board | Appointed | 2024-08-14 |
| Vishwas Seshadri | Class 2 director | Appointed | 2024-04-24 |
| Leila Alland | Class 2 director | Appointed | 2024-04-24 |
| Michael Amoroso | Chairman of the Board | Appointed | 2023-04-11 |
| Joseph Vazzano | Chief Financial Officer | Appointed | 2022-03-09 |
| Edward Carr | Chief Accounting Officer | Resigned | 2022-03-09 |
| Edward Carr | Chief Financial Officer | Resigned | 2022-03-09 |
Key facts
CIK
318306
CUSIP
00289Y206
13F (30d)
121 filings
120 filers
Visit website
Investor relations